FCDS 2013-2014
QUALITY IMPROVEMENT EDUCATION AND TRAINING

FCDS Webcast Series
Steven Peace, BS, CTR
Mayra Espino, BA, RHIT, CTR
October 24, 2013
# Continuing Education Hours

<table>
<thead>
<tr>
<th>NCRA CEU #</th>
<th>Date</th>
<th>Event</th>
<th>Sponsor</th>
<th>CEU Hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013-114</td>
<td>7/25/2013 - 7/26/2013</td>
<td>FCDS Annual Conference, Sunrise, FL</td>
<td>FCDS</td>
<td>8.25</td>
</tr>
</tbody>
</table>
Presentation Outline

• Rule Makers for National Data Collection
• NPCR Program Standards 2012-2017
• NAACCR Certification Criteria

• FCDS Data Quality Program
  • Data Quality Goals
  • Data Quality Policy
  • Data Quality Activities
  • Data Quality Audits
  • Data Quality Reports

• FCDS Education and Training Program
• FCDS “Future Vision”
• Current FCDS QC Issues
Rule Makers for National Data Collection

CDC NPCR – FCDS Participates in NPCR
- State/Central Registries – 98% of US Population – State/Federal Legislation
- Data Acquisition Manual

ACoS Commission on Cancer
- ACoS Cancer Programs – CoC Cancer Program Standards - Voluntary
- National Program for Breast Centers – NAPBC Standards – Voluntary
- FORDS

NCI SEER Program
- 26 percent of African Americans, 41 percent of Hispanics, 43 percent of American Indians and Alaska Natives, 54 percent of Asians, and 71 percent of Hawaiian/Pacific Islanders.
- SEER Program Manual

26 percent of African Americans, 41 percent of Hispanics, 43 percent of American Indians and Alaska Natives, 54 percent of Asians, and 71 percent of Hawaiian/Pacific Islanders.
NPCR Program Standards, 2012-2017

Program Manual

National Program of Cancer Registries

Version 2.0
NPCR Program Standards, 2012-2017

All funded programs must meet the following standards:

- Legislative Authority
- Administration
- Data Collection, Content, and Format
- Electronic Data Exchange
- Data Completeness/Timeliness/Quality
- Linkages
- Data Quality Assurance and Education
- Data Use and Data Monitoring
- Data Submission
- Collaborative Relationships
NPCR Program Standards, 2012-2017

Data being evaluated for the **National Data Quality Standard** (formerly known as the **24-Month Standard**), must meet the following five data quality criteria:

- Data are **95% complete** based on observed-to-expected cases as computed by CDC.
- There are **3% or fewer death-certificate-only** cases.
- There is a **1 per 1,000 or fewer unresolved duplicate** rate.
- The **maximum percent missing** for critical data elements are:
  - 2% age
  - 2% sex
  - 3% race
  - 2% county
- **99% pass** a CDC-prescribed set of standard edits.
NPCR Program Standards, 2012-2017

• Data being evaluated for the **Advanced National Data Quality Standard** (formerly known as the **12-Month Standard**), must meet the following data quality criteria:
  • Data are **90% complete** based on observed-to-expected cases as computed by CDC.
  • There is a **2 per 1,000 or fewer unresolved duplicate rate**
  • The **maximum percent missing** for critical data elements are:
    • 3% age
    • 3% sex
    • 5% race
    • 3% county
  • **97% pass** a CDC-prescribed set of standard edits.
NPCR Program Standards, 2012-2017

- Data Quality Assurance and Education
  - The central cancer registry has an overall program of quality assurance that is defined in the registry operations manual.
  - The quality assurance program consists of, but is not limited to:
    - A designated certified tumor registrar (CTR) responsible for the quality assurance program.
    - Quality assurance activities should be conducted by qualified experienced CTR(s) or CTR-eligible staff.
    - At least once every 5 years, a combination of case-finding and re-abstracting audits from a sampling of source documents are conducted for each hospital-based reporting facility, and may include external audits by CDC or SEER.
    - Data consolidation procedures are performed according to the central cancer registry protocol and nationally accepted abstracting and coding standards as available.
    - Audits of a routine sample of consolidated cases at the central cancer registry.
    - Feedback is provided to reporting sources on data quality and completeness.
The central cancer registry has an overall education program that is defined in the registry operations manual.

The education program consists of, but is not limited to:

- Training for central cancer registry staff and reporting sources to assure high quality data.
- A designated education/training coordinator who is a qualified, experienced CTR.
- Where feasible, the education/training coordinator may be regionally-based, such that CDC-NPCR applicants collaborate to identify one applicant to provide the education/training coordinator for activities to be carried out in the full region.
Annual Report to the Nation
NAACCR Gold Certification Criteria

- Case ascertainment = 95% or higher completeness.
- < 3% of cases are reported by Death Certificate Only.
  - < 0.1% duplicate case reports are in the file.
  - 100% error-free data.
- < 2% of cases are missing age, sex, or county.
  - < 3% of cases are missing race.
- The file is submitted to NAACCR for evaluation within 23 months of the close of the diagnosis year under review.
Gold and Silver Level Certification Status
of NAACCR U.S. Cancer Registries for 2010 Data

- Gold Certified
- Silver Certified
The FCDS Data Quality Program
FCDS Data Quality Pyramid

COMMUNICATION
COMPLETENESS
ACCURACY/DATA QUALITY
TIMELINESS
REINFORCEMENT
REWARDS
FCDS Quality Improvement

Measure → Policies → Report → Identify → Fix → Measure

Configure

Connect

Data Sources
Foundation - Communication/Education

- Technical Answers by Telephone or E-mail
- Email (E-Mail Blast for Urgent or Timely Information)
- Email (Individual for questions or if you are having problems)
- FCDS IDEA (QC Review, Edits/Corrections, Documentation)
- FCDS RECAP – FCDS Internal Tool for Data Processing
- FCDS On-Line Abstractor Training Course
- FCDS Annual Meeting – face-to-face
- FCDS Memo – every two months
- FCDS Web Broadcasts
FCDS Data Quality Program - Goals

**Goals:**
- Population-Based Reporting
- Highest Quality Data Possible
- Confidentiality, Privacy, Data Security

**Objectives:**
- Improve Communications
- Improve Feedback Loop
- Improve Completeness
- Improve Data Quality
- Improve Usefulness
- Improve Timeliness
- Improve Education
- Improve Reports
- Improve Training
FCDS Data Quality Program - Goals

• Establish, perform, manage Quality Improvement/Quality Control projects
• Apply national and internal standards for data collection, aggregation, etc
• Systematically measure performance against those standards
• Assess outcomes and performance measures
• Develop measurement and evaluation tools
• Develop quality enhancement strategies
• Assess registry needs and satisfaction
• Monitor completeness, quality and timeliness
• Provide education and training to improve data quality
FCDS Data Quality Program - Methods

- Florida Cancer Reporting Legislation
- Florida Public Health Administration Rules

- FCDS Policy and Procedures (FCDS DAM)
  - Internal Policy and Procedures
  - External Policy and Procedures
  - Monitoring Data Quality and Performance

- Quality Assurance / Quality Improvement Activities
  - Monitor operations workflow and data quality and take action to improve future quality, maximizing correct reporting and characterizing the reporting process in measurable terms.

- Perform External Linkage to Improve Data
  - Obtain and/or validate data items by linking central cancer registry databases with clinical and non-clinical state and national databases
    - Using death certificate data to add missing vital status and race
    - Using claims data to complete first course of treatment data
FCDS Data Quality Program - Methods

- FCDS Policy
  - FCDS Abstractor Code Requirement
  - FCDS EDITS Requirement
  - Text Documentation Requirement
  - Deadlines and IT Security
- FCDS Procedures
  - FCDS IDEA – Communication/Transmission
  - FCDS Internal Data Processing Monitoring
  - FORCES/CORRECTIONS/DELETIONS
  - Patient and Tumor Linkage & Consolidation
- FCDS Monitoring / Audits
  - Audits for Completeness
  - Audits for Timeliness
  - Audits for Accuracy
- FCDS Data Quality Reports
  - Quarterly/Annual Status Reports
  - Ad Hoc Reports
  - Audit Results
The 2012 Florida Statutes

Title XXIX  Chapter 381  View Entire Chapter
PUBLIC HEALTH  PUBLIC HEALTH: GENERAL PROVISIONS
381.0031  Epidemiological research; report of diseases of public health significance to department.—

(1)  The department may conduct studies concerning the epidemiology of diseases of public health significance affecting people in Florida.

(2)  Any practitioner licensed in this state to practice medicine, osteopathic medicine, chiropractic medicine, naturopathy, or veterinary medicine; any hospital licensed under part I of chapter 395; or any laboratory licensed under chapter 483 that diagnoses or suspects the existence of a disease of public health significance shall immediately report the fact to the Department of Health.

(3)  An animal control officer operating under s. 828.27, a wildlife officer operating under s. 379.3311, or an animal disease laboratory operating under s. 585.61 shall report knowledge of any animal bite, diagnosis of disease in an animal, or suspicion of a grouping or clustering of animals having similar disease, symptoms, or syndromes that may indicate the presence of a threat to humans.

(4)  The department shall periodically issue a list of infectious or noninfectious diseases determined by it to be a threat to public health and therefore of significance to public health and shall furnish a copy of the list to the practitioners listed in subsection (2). The list shall be based on the
FCDS Data Quality Program - Policy

FCDS Abstractor Code – A National Model for QC
## FCDS Text Documentation Requirements

<table>
<thead>
<tr>
<th>Data Items Requiring Complete Text Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Date of DX</strong></td>
</tr>
<tr>
<td><strong>Seq No</strong></td>
</tr>
<tr>
<td><strong>Sex</strong></td>
</tr>
<tr>
<td><strong>Primary Site</strong></td>
</tr>
<tr>
<td><strong>Subsite</strong></td>
</tr>
<tr>
<td><strong>Laterality</strong></td>
</tr>
<tr>
<td><strong>Histologic Type</strong></td>
</tr>
<tr>
<td><strong>Behavior Code</strong></td>
</tr>
<tr>
<td><strong>Grade</strong></td>
</tr>
<tr>
<td><strong>CS Tumor Size</strong></td>
</tr>
<tr>
<td><strong>CS Ext</strong></td>
</tr>
<tr>
<td><strong>CS Tumor Ext/Eval</strong></td>
</tr>
<tr>
<td><strong>Regional Nodes Positive</strong></td>
</tr>
<tr>
<td><strong>Regional Nodes Examined</strong></td>
</tr>
<tr>
<td><strong>CS LN</strong></td>
</tr>
<tr>
<td><strong>CS LN Eval</strong></td>
</tr>
<tr>
<td><strong>CS Mets</strong></td>
</tr>
<tr>
<td><strong>CS Mets Eval</strong></td>
</tr>
<tr>
<td><strong>All FCDS Req’d SSFs</strong></td>
</tr>
</tbody>
</table>
FCDS Data Quality Program - Policy

FCDS Text Documentation Requirements

APPENDIX L FCDS TEXT DOCUMENTATION REQUIREMENTS

Text documentation is an essential component of a complete electronic abstract and is heavily utilized in quality control, to validate data at time of FCDS and NPCR Audits, and for special studies. Text documentation is required to justify coded values and to supplement information not transmitted with coded values. FCDS recommends that abstractors print and post this document for easy reference. Adequate text is a data quality indicator and will be major part of QC.

Text documentation should always include the following components:
- Date(s) – include date(s) references – this allows the reviewer to determine event chronology
- Date(s) – note when date(s) are estimated [i.e. Date of DX 3/15/2011 (est.)]
- Location – include facility/physician/other location where the event occurred (test/study/treatment/other)
- Description – include description of the event (test/study/treatment/other) – include positive/negative results
- Details – include as much detail as possible – document treatment plan even if treatment is initiated as planned
- Include “relevant-to-this-person/cancer” information only – edit your text documentation
- DO NOT REPEAT INFORMATION from section to section
- DO USE Standard Abbreviations (Appendix B)
- DO NOT USE non-standard or stylistic shorthand
- Enter “N/A” or “not available” when no information is available related to any specific text area.
FCDS Data Quality Program - Policy

FCDS Text Documentation Requirements

APPENDIX L FCDS TEXT DOCUMENTATION REQUIREMENTS

<table>
<thead>
<tr>
<th>Text Data Item Name</th>
<th>Text Documentation Source and Item Description</th>
<th>Example:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAACCR Item #</td>
<td>Field Length</td>
<td>FCDS Required Text Documentation</td>
</tr>
<tr>
<td>Text - Operative Report</td>
<td>Enter text information from surgical operative reports (not diagnostic needle, incisional biopsy). Include observations at surgery, tumor size, and extent of involvement of primary or metastatic sites. Date of procedure, facility where procedure was performed, type of surgical procedure, detailed surgical findings, documentation of residual tumor, evidence of invasion of surrounding areas</td>
<td>Example: 4/12/11 (Hosp xyz) right colon resection - Pt was found to have extensive disease in the pelvis (carcinomatosis) and resection was aborted</td>
</tr>
<tr>
<td>NAACCR Item #2560</td>
<td>Field Length = 1000</td>
<td></td>
</tr>
<tr>
<td>DX Text - Pathology</td>
<td>Enter text information from cytology and histopathology reports. Date of specimen/resection, facility where specimen examined, pathology accession #, type of specimen, final diagnosis, comments, addenda, supplemental information, histology, behavior, size of tumor, tumor extension, lymph nodes (removed/biopsied), margins, some special histo studies</td>
<td>Example: 2/5/11 (Hosp xyz) - Path Acc # - Rectum: Final Dx: adenoca, 2.5cm, ext. to pericolic fat. 1/22 lymph nodes + , margins neg, S100 stain is positive (melanoma, sarcoma)</td>
</tr>
<tr>
<td>NAACCR Item #2570</td>
<td>Field Length = 1000</td>
<td></td>
</tr>
<tr>
<td>DX Text - Staging</td>
<td>Enter Details of Collaborative Stage and other stage information not already entered in other text areas. Include specific Information on Tumor Size, Extension of Primary Tumor, Metastatic Sites, etc. Organs involved by direct extension, size of tumor, status of margins, sites of distant metastasis, special consideration for staging, overall stage, etc. Text for SSF documentation if not under Labs.</td>
<td>Example: 2/15/11 - T2aN1a per path, distant mets in lungs, ER/PR neg, HER2 neg by IHC method</td>
</tr>
<tr>
<td>NAACCR Item #2600</td>
<td>Field Length = 1000</td>
<td></td>
</tr>
<tr>
<td>RX Text - Surgery</td>
<td>Enter text describing the surgical procedure(s) performed as part of 1st course treatment. Treatment plan, date surgery performed, type of procedure, facility where surgery was performed</td>
<td>Example: 2/15/11 (Hosp xyz) - rt breast mrm w/ax ln dissection</td>
</tr>
<tr>
<td>NAACCR Item #2610</td>
<td>Field Length = 1000</td>
<td></td>
</tr>
</tbody>
</table>
FCDS transitioned from an Oracle-based edits program written by FCDS contractors to the National Standard EDITS Metafile in September 2010.

Standard EDITS include Field-Item, Inter-Item and Intra-Item Edits

- Edits validate codes, crosscheck relationships between data items (male with prostate cancer) and checks for blank fields.

- The FCDS EDITS Metafile was created for Florida, specifically to accommodate the reporting of historical cases among other FCDS special coding requirements

- FCDS has also included edits in the metafile for common abstracting errors identified through re-abstracting audits.
FCDS Data Quality Program - Policy

- Deadlines and Data Monitoring Policy and Procedures
- Confidentiality of Protected Health Information
- IT Security Policy and Procedures
- Patient Privacy and HIPAA
- No Paper Policy
- Other
FCDS Data Quality Program - Procedures

- FCDS EDITS Metafile
- FCDS Correction / FORCE / Delete
- FCDS QC Review of Every 25\textsuperscript{th} Record – Visual Editing
- Patient and Tumor Linkage and Consolidation Procedures
- FCDS Audit Findings Link Back to Education
- FCDS Data Use Link Back to Procedures
FCDS Data Quality Program - EDITS
Standard Sources for EDITS

- NCI SEER
- CDC NPCR
- ACOS COC
- Other States
- Collaborative Stage
- FCDS for Florida-Specific
- NAACCR EDITS Working Group
FCDS EDITS Check For Conditions

- Blank Field Checks – Single Item Edit
- Valid Code Checks – Single Item Edit
- Valid Date Checks – Single Item Edit
- Inter-Field Edits – Relationships Between Items
- Inter-Record Edits – Relationships Between Cases
- CS Edits – Core
- CS Edits – Staging
- CS Edits – SSFs
- Inter-Field CS and Other Item Edits (scope, surg)
- Link CS Stage and SSF Data to Treatment Plan
Number of Edits Over Time
Total Edit Failures Over Time
<table>
<thead>
<tr>
<th>Category</th>
<th>Error #</th>
<th>Warning</th>
<th>Force</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Edits</td>
<td>81</td>
<td>N</td>
<td>Y</td>
<td>Invalid Morphology for patient over age 5 based on ICD-O-3</td>
</tr>
<tr>
<td>Age Edits</td>
<td>82</td>
<td>N</td>
<td>Y</td>
<td>Invalid Site for patient under age 15</td>
</tr>
<tr>
<td>Class of Case Edits</td>
<td>149</td>
<td>N</td>
<td>N</td>
<td>Class of Case equal 38 (autopsy only) or 49 (DCO) and Vital Status not</td>
</tr>
<tr>
<td>Class of Case Edits</td>
<td>150</td>
<td>N</td>
<td>N</td>
<td>equal 0 (dead)</td>
</tr>
<tr>
<td>Collaborative Staging Edits</td>
<td>1</td>
<td>N</td>
<td>N</td>
<td>There is missing data (blank field) or invalid characters exist in the</td>
</tr>
<tr>
<td>Collaborative Staging Edits</td>
<td>287</td>
<td>N</td>
<td>N</td>
<td>data for this data item</td>
</tr>
<tr>
<td>Dx Confirmation Code Edits</td>
<td>219</td>
<td>N</td>
<td>Y</td>
<td>ICD-O-3 Behavior 2 requires Dx Confirmation 1, 2, or 4</td>
</tr>
<tr>
<td>Grade Code Edits</td>
<td>204</td>
<td>N</td>
<td>N</td>
<td>Grade must = 6 for this ICD-O-3 Morph Code</td>
</tr>
<tr>
<td>Grade Code Edits</td>
<td>834</td>
<td>N</td>
<td>N</td>
<td>Grade should be coded to Implied Grade for this histology</td>
</tr>
<tr>
<td>Grade Code Edits</td>
<td>841</td>
<td>N</td>
<td>N</td>
<td>Grade is not valid</td>
</tr>
<tr>
<td>Invalid Codes Edits</td>
<td>10</td>
<td>N</td>
<td>N</td>
<td>not valid</td>
</tr>
<tr>
<td>Invalid Codes Edits</td>
<td>12</td>
<td>N</td>
<td>N</td>
<td>ICD-O-2 Morphology not valid</td>
</tr>
<tr>
<td>Invalid Codes Edits</td>
<td>102</td>
<td>N</td>
<td>N</td>
<td>Facility Code not valid</td>
</tr>
<tr>
<td>Probable Duplicate Edits</td>
<td>106</td>
<td>N</td>
<td>Y</td>
<td>Probable duplicate detected in master file</td>
</tr>
<tr>
<td>Sequence Edits</td>
<td>40</td>
<td>N</td>
<td>Y</td>
<td>Sequence greater than zero with Ill-Defined primary site, Ill-Defined</td>
</tr>
<tr>
<td>Sex/Site Edits</td>
<td>11</td>
<td>N</td>
<td>N</td>
<td>Lymphoma, or Ill-Defined Leukemia</td>
</tr>
<tr>
<td>Site Code Edits</td>
<td>52</td>
<td>N</td>
<td>N</td>
<td>Site equals C50.* and Morphology equals 8521</td>
</tr>
<tr>
<td>Site/Morphology Edits</td>
<td>190</td>
<td>N</td>
<td>Y</td>
<td>ICD-O-3 Morphology not valid with Site or not reportable to FCDS</td>
</tr>
<tr>
<td>Site/Morphology Edits</td>
<td>207</td>
<td>N</td>
<td>Y</td>
<td>ICD-O-3 morphology cannot equal 8521/3 when site = C50.*. Verify</td>
</tr>
<tr>
<td>Therapy and Date Edits</td>
<td>268</td>
<td>N</td>
<td>Y</td>
<td>morphology code</td>
</tr>
<tr>
<td>Therapy and Date Edits</td>
<td>269</td>
<td>N</td>
<td>Y</td>
<td>Breast, Prostate. Transplant/Endocr Surg Rx Date must be less than 365</td>
</tr>
<tr>
<td>Warnings</td>
<td>86</td>
<td>Y</td>
<td>N</td>
<td>days after Diagnosis Date</td>
</tr>
<tr>
<td>Warnings</td>
<td>359</td>
<td>Y</td>
<td>N</td>
<td>WARNING: Other Rx is greater than 0 or less than 9</td>
</tr>
<tr>
<td>Warnings</td>
<td>989</td>
<td>Y</td>
<td>N</td>
<td>WARNING: Please verify this case is reportable. Check Sect. I of the</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FCDS DAM for reportability guidelines</td>
</tr>
</tbody>
</table>
FCDS and National EDITS – Coming Soon!

• Updates to SEER Site/Type Table
  • 2013 Hematopoietic and Lymphoid Neoplasm Site/Type
  • 2014 Hematopoietic and Lymphoid Neoplasm Site/Type
  • 2015 ICD-O-3 Updates – New Histology Codes and New Site/Type
  • General Updates to Site/Type Combinations
• Increasingly Complex Inter-Field EDITS
• Treatment EDITS linked to cancer profile
• Treatment EDITS linked to cancer stage
• Clinical Edit Checks
  • NCCN/ASCO Guidelines
  • NCDB Submission Edits
  • RQRS (Rapid Quality Reporting System)
  • CP3R (Cancer Program Practice Profile Reports)
Staying Current - FCDS EDITS

- Understand FCDS EDIT and what each is designed to do
- Review FCDS EDITS Messages – make them more clear
- Identify FCDS EDITS that are “FORCEABLE”
- Understand FCDS EDITS/CORRECTION/FORCE Process
- Understand FCDS FC/QC responsibilities and expectations
  - External FCDS EDITS Metafile to be used by Registrars
  - Internal FCDS EDITS Metafile used by FCDS
  - FCDS Metafile Excel Sheet documenting changes
- Registrar Interest in Learning How to Use Edit Writer
Staying Current - FCDS EDITS

http://fcds.med.miami.edu/inc/downloads.shtml#fcdsdatafiles

What’s New / Downloads

FCDS Data Files

- **Independent Contractor List (comma separated text file)** This list of independent contractors is provided as a courtesy and should not be considered a complete list (as the list is updated only twice per year). Additionally, the Florida Cancer Data System makes no recommendations about the individual’s abilities or skills and takes no responsibility for the quality of their work. Inclusion on this list is by request of the independent contractor.

- **Zip code, Fips County, Florida City Name Verification file (comma separated text file)** This can be used by abstracting vendors to lower the number of county/zip/city errors for abstracts submitted to FCDS. The [USPS Zip/County/Address Lookup Page](http://www.usps.com/maps/ziplookup.jsp) has the very latest zipcodes.

- **Current list of FCDS Edit messages as a comma separated file.** This link downloads the latest FCDS Edit Messages with Force/Warning flags. Sorted by category/edit#

- **FCDS/NAACCR EDITs Metafile - Updated metafiles will be posted here when there are corrections/changes, so check this page for new versions:**
  - 13.0A Metafile (July 28), posted 08/8/2013 10:50am, Metafile changes
### Staying Current - FCDS EDITS Metafile

<table>
<thead>
<tr>
<th>Metafile Version</th>
<th>Modification Date</th>
<th>Edit</th>
<th>Edit Name</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1351</td>
<td>Addr at DX–Country (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1352</td>
<td>Addr at DX–Country, Date of Diagnosis (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1353</td>
<td>Addr at DX–Country, State (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1354</td>
<td>Addr Current–Country (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1355</td>
<td>Addr Current–Country, Date of Diagnosis (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1356</td>
<td>Addr Current–Country, State (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>0009</td>
<td>Birthplace (SEER POB)</td>
<td>DELETED from both FCDS edits sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1357</td>
<td>Birthplace–Country (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1358</td>
<td>Birthplace–Country, Date of Diagnosis (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1359</td>
<td>Birthplace–Country, State (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1360</td>
<td>Birthplace–State (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1361</td>
<td>Birthplace–State, Date of Diagnosis (NAACCR)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>0969</td>
<td>CS Ext, LN, Mets at DX, SSF 1, Retinoblastoma (CS)</td>
<td>Added SEER IF number (IF349)</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>0971</td>
<td>CS Ext, LN, Mets at DX, SSF 3, Prostate (CS)</td>
<td>Added SEER IF number (IF350)</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1367</td>
<td>CS Ext, Surg, TS/Ext Eval, Prostate (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1369</td>
<td>CS Ext,TS/Ext Eval, SSF 1, MelanomaConjunctiva (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>0287, 0447, 0451, 0482, 1101-1103</td>
<td>CS Extension, CS Lymph Nodes, CS Mets at DX (CS)</td>
<td>Updated last paragraph of description: changed &quot;For all other sites&quot; to &quot;If schema is not Breast, Bladder, KidneyRenalPelvis, Urethra or UrinaryOther&quot;</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1368</td>
<td>CS Extension, Histology, Grade, Thyroid (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1371</td>
<td>CS Extension, SSF 1, Conjunctiva Schema (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1372</td>
<td>CS Extension, SSF 1, MelanomaConjunctiva (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1373</td>
<td>CS Extension, SSF 2, Lung Schema (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1376</td>
<td>CS Extension, SSF 2, MelanomaChoroid (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>13A</td>
<td>06/25/13</td>
<td>1377</td>
<td>CS Extension, SSF 2, MelanomaCiliaryBody (CS)</td>
<td>New edit - added to both edit sets</td>
</tr>
<tr>
<td>Category</td>
<td>Error Code</td>
<td>Warning Flag</td>
<td>Force Flag</td>
<td>Description</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------------</td>
<td>--------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Age Edits</td>
<td>81</td>
<td>N</td>
<td>Y</td>
<td>Invalid Site and Morphology for patient over age 5 based on ICD-O-2</td>
</tr>
<tr>
<td>Age Edits</td>
<td>82</td>
<td>N</td>
<td>Y</td>
<td>Invalid Site for patient under age 15</td>
</tr>
<tr>
<td>Class of Case Edits</td>
<td>149</td>
<td>N</td>
<td>N</td>
<td>Class of Case equal 38 (autopsy only) or 49 (DCO) and Vital Status not equal 0 (dead)</td>
</tr>
<tr>
<td>Class of Case Edits</td>
<td>520</td>
<td>N</td>
<td>N</td>
<td>If Class of Case equal 38 (autopsy only), then Date of Diagnosis and Date of Last Contact must be the same date.</td>
</tr>
<tr>
<td>Collaborative Staging Edits</td>
<td>287</td>
<td>N</td>
<td>N</td>
<td>If CS Extension is 950, CS Lymph Nodes cannot = 000 and CS Mets at DX cannot be 00</td>
</tr>
<tr>
<td>Collaborative Staging Edits</td>
<td>288</td>
<td>N</td>
<td>N</td>
<td>If CS schema is not KaposiSarcoma, MelanomaSkin, Conjunctiva, MelanomaConjunctiva, MelanomaChoroid, MelanomaIris, MelanomaCiliaryBody, or LymphomaOcularAdnexa: If CS Extension = 950, then CS Tumor Size must = 000.</td>
</tr>
<tr>
<td>Grade Code Edits</td>
<td>1263</td>
<td>N</td>
<td>N</td>
<td>Unknown Primary Site (C809), Grade must = 9</td>
</tr>
<tr>
<td>Grade Code Edits</td>
<td>1300</td>
<td>N</td>
<td>N</td>
<td>Grade must = 5, 8, or 9 for this ICD-O-3 Morph code</td>
</tr>
<tr>
<td>Invalid Codes Edits</td>
<td>10</td>
<td>N</td>
<td>N</td>
<td>Site not valid</td>
</tr>
<tr>
<td>Invalid Codes Edits</td>
<td>14</td>
<td>N</td>
<td>N</td>
<td>Abstractor code not valid</td>
</tr>
<tr>
<td>Morphology Code Edits</td>
<td>839</td>
<td>N</td>
<td>Y</td>
<td>Histology is not valid</td>
</tr>
<tr>
<td>Morphology Code Edits</td>
<td>840</td>
<td>N</td>
<td>Y</td>
<td>Invalid Histology for in situ</td>
</tr>
<tr>
<td>Out of Range Edits</td>
<td>19</td>
<td>N</td>
<td>N</td>
<td>County Residence Current out of range (11-77, 88 or 90) or not numeric</td>
</tr>
<tr>
<td>Out of Range Edits</td>
<td>22</td>
<td>N</td>
<td>N</td>
<td>Hispanic Origin is out of range (0 through 7 or 9)</td>
</tr>
<tr>
<td>Probable Duplicate Edits</td>
<td>106</td>
<td>N</td>
<td>Y</td>
<td>Probable duplicate detected in master file</td>
</tr>
<tr>
<td>Sequence Edits</td>
<td>40</td>
<td>N</td>
<td>Y</td>
<td>Sequence greater than zero with Ill-Defined primary site, Ill-Defined Lymphoma, or Ill-Defined Leukemia</td>
</tr>
<tr>
<td>Sequence Edits</td>
<td>63</td>
<td>N</td>
<td>N</td>
<td>If Date of 1st Contact is less than 1981, Sequence Number--Hospital cannot = 00 or 60</td>
</tr>
<tr>
<td>Therapy and Date Edits</td>
<td>113</td>
<td>N</td>
<td>N</td>
<td>If Surgery Primary Site = 00 and Scope Reg LN Surg = 0 and Surg Oth/Reg/Dist = 0 then Surg Date must equal 00000000</td>
</tr>
<tr>
<td>Therapy and Date Edits</td>
<td>119</td>
<td>N</td>
<td>N</td>
<td>If RX Summ--Chemo = 00, 82, or 85-87 (chemo not given) then RX Date--Chemo must be blank and RX Date--Chemo Flag field must = 11 (no chemo).</td>
</tr>
<tr>
<td>Warnings</td>
<td>60</td>
<td>Y</td>
<td>N</td>
<td>WARNING: Other Rx is greater than 0 or less than 9</td>
</tr>
<tr>
<td>Warnings</td>
<td>359</td>
<td>Y</td>
<td>N</td>
<td>WARNING: Please verify this case is reportable. Check Sect. I of the FCDS DAM for reportability guidelines</td>
</tr>
</tbody>
</table>
## 2012 Corrections/Deletions/FORCES

<table>
<thead>
<tr>
<th>All Cases Processed</th>
<th>Receipt Date 2012</th>
<th>% of Total Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good</td>
<td>182,449</td>
<td>93.8%</td>
</tr>
<tr>
<td>Corrected</td>
<td>5,146</td>
<td>2.6%</td>
</tr>
<tr>
<td>Forced</td>
<td>2,866</td>
<td>1.5%</td>
</tr>
<tr>
<td>Deleted</td>
<td>1,965</td>
<td>1.0%</td>
</tr>
<tr>
<td>Total Processed</td>
<td>194,426</td>
<td>100%</td>
</tr>
</tbody>
</table>
## 2012 QC Review Summary

<table>
<thead>
<tr>
<th>QC Review/Visual Edit</th>
<th># Cases</th>
<th>% of Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cases Processed</td>
<td>194,426</td>
<td>100%</td>
</tr>
<tr>
<td>Total Cases Selected</td>
<td>10,007</td>
<td>4.6% of ALL</td>
</tr>
<tr>
<td>No Additional Review</td>
<td>7,396</td>
<td>74% of Sample</td>
</tr>
<tr>
<td>QC Review Follow-Back</td>
<td>2,611</td>
<td>26% of Sample</td>
</tr>
<tr>
<td>2nd Review - No Change</td>
<td>834</td>
<td>8.3%</td>
</tr>
<tr>
<td>2nd Review - FORCE</td>
<td>50</td>
<td>0.5%</td>
</tr>
<tr>
<td>2nd Review - CORRECT</td>
<td>1,693</td>
<td>16.9%</td>
</tr>
<tr>
<td>2nd Review - DELETE</td>
<td>34</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
Visual Editing of Cases

• Rationale for Visual Editing

• Standards for Visual Editing

• Timing for Visual Editing
  • New Abstractor Review
  • Automated QC Review
  • Individual Case Corrections/Forces
  • Case Consolidation
  • Special Studies
  • Audits
FCDS Data Quality Program – Every 25th

FCDS QC Visual Review - Every 25th Record

- 2012 Added All Male Breast and All Pediatric Neoplasms to QC Review

**GOAL:** Evaluate whether or not the case makes sense as coded or is something missing or unusual that edits would not catch. Does the case make sense as coded or is something missing or “off” with case as coded.

By selecting one of every 25th records received plus male breast and all pediatric cases, FCDS visually edits at least 5% of the total cases submitted each year. Other cases visually edited are cases being evaluated for FORCES, Corrections, Special Studies, and During Data Use (up to 10% of annual cases).

- The QC Abstract Review Process is a 3-step process - fully automated.
  - **Step 1:** initial review
  - **Step 2:** feedback to/from the registrar with opportunity to defend coding
  - **Step 3:** third party mediation assesses the first reviewer’s findings, the facility’s comments, any recommended corrections, or feedback and come to a final determination on the case – the mediators decision is final

- Records with discrepant data must be resolved by the reporting facility.

- “Agree”, “OK”, “Done” are NOT Acceptable Responses to Inquiries
Visual Review – What We Are Seeing

- **Treatment Documented in Text BUT NOT CODED**
  - If you get a QC Review asking you to code treatment and in your system it is coded – FCDS didn’t get the code – you must contact your vendor to see why not transmitted.

- **Replies on QC Review still are lacking clear answers**
  - “ok” – “updated abstract” – “agree” are NOT answers.

- **Replies on QC Change in Primary Site MUST include complete RESTAGING** – this is often overlooked and must not only be restaged – but must be in text fields.

- **Treatment Planned versus Treatment Delivered - CONFIRM**
Visual Review – What We Are Seeing

• You CAN copy and paste from EMR – BUT PLEASE EDIT the copy and paste and be sure it is relevant / complete AND be sure that you include the FINAL DIAGNOSIS.

• EDIT – EDIT – EDIT – some of you ramble and it does not make sense or you copy and paste without reading text

• Some facilities not coding complete first course treatment and FCDS knows patient had additional surgery because we get the e-path report from your facility showing txs.

• Okay to save time – but please do not sacrifice quality or complete reporting or it will come back to you with questions
Visual Review – The Panoramic View

- Are there many blank spaces?
- Is code 9 (unknown) used frequently?
- Are there other numeric red flags (.8, 88, 8)?
- Are all dates in logical order?
- Are text fields significantly different from coded field translations?
- Is treatment appropriate for site and stage?
- Is there logical progression from stage at initial diagnosis to recurrence and recurrence sites?
- Does the abstract tell a complete story?
Visual Review – Demographic Items

• Surname – Spanish origin
• Race – Surname – Place of birth
• Area code – County
• Date of birth – Date of diagnosis
• Sex – Name
• Sex – Primary site
• Age – Occupation
• Age – Marital status
• Age – Primary site and histology
• Address – Place of diagnosis
• City -- County
Visual Review – Diagnosis Items

- Primary site code – Text
- Histology code – Text
- Site – Laterality – Histology
- Behavior – Diagnostic confirmation
- Dx confirmation – Histology > 8000
- Are dates in logical sequence?
- Is Dx date the earliest documented?
- Class of case – Facility referred to/from
- Dx date – Place of diagnosis
- Site – Type of admission
- Sequence no. – Other primaries
Visual Review – Staging Items

- Stage – Primary site
- CS codes – Procedures text
- CS Extension – Summary stage – cT / pT
- CS Extension – SSFs (by site)
- Age – Pediatric stage
- CS Lymph Nodes – Summary stage – cN / pN
- CS Lymph Nodes – SSFs (by site)
- Tumor size > 100
- Nodes pos/exam – Surgery
- CS Mets at Dx – Summary stage – cM / pM
- Staging basis – Dates of treatment
Visual Review – Treatment Items

- Planned first course listed?
- Treatment – Primary site – Stage
- Treatment code – Procedure name
- Treatment – Facility referred from/to
- Surgery – Operative findings text
- Surgery – Pathology text
- Date 1st surg – Date most definitive surg
- Date most definitive surg – Date surg discharge
- Surg prim site – Margins
- Surg prim site – Scope reg LN
- Surg prim site – Reason no surg
Visual Review – Treatment Items

- Surgery – Radiation – RT/surgery seq
- Date RT start – Date RT end
- Location of RT – Facility referred from/to
- RT treatment volume – Reason no RT
- RT treatment volume – Boost volume
- Systemic tx – Primary site
- Systemic tx date – Chemo – Hormone – Immunotherapy
- Systemic tx date – Date most definitive surgery – Systemic/surgery sequence
- Hematologic Transplant & Endocrine Procedure – Primary site
- RT treatment volume – Palliative care
Patient and Tumor Match, Link & Consolidate

BEST INFORMATION AVAILABLE FROM ALL SOURCES
Patient and Tumor Match, Link & Consolidate

- Electronic edits, Visual Editing, Patient and Tumor Matching
- Comparison of individual data and data items
- Records received are checked for duplicate reporting
- Multiple reports for same patient are merged to capture most complete demographic data
- Multiple reports for same patient are checked for new tumors (same vs. new primary)
- Multiple reports for the same tumor are merged to capture most complete diagnostic, staging and treatment data
Patient and Tumor Match, Link & Consolidate

PROCEDURES MANUAL

Patient and Tumor Consolidation

METHODOLOGY
Assumptions
Use of Class of Care
Patient Consolidation Rules
Current MPH for Solid Tumors
MPH for Hematopoietic and Lymphoid Neoplasms
Workflow for Rules-Based Tumor Consolidation, DX, Stage, TX, F/U
Individual Data Item Consolidation, Status and Review Flag Rules
Grouped Data Items consolidation, Status and Review Flag Rules
FCDS and NPCR EDITS for Consolidated Record
Clinical EDIT Checks for Complete Treatment
Quality Control
FCDS Data Quality Program - Audits

• Introduction to FCDS Audits – Topic Selection / Protocol

• Audits to Assess Completeness

• Audits to Assess Timeliness

• Audits to Assess Accuracy

• Reconciliation Process

• External Audits

• Other
FCDS Data Quality Program - Audits

- Annual audits
  - Completeness
  - Timeliness
  - Data Quality/Validation

- Targeted audits
  - Identify extent of specific problems
  - Identify individual data collector training needs
  - Review and improve data quality in problem areas

- Random audits
  - Validate central registry data for research purposes
  - Identify unknown problem areas
  - Identify general data collector training needs
  - Review and improve data quality in unknown areas
FCDS Data Quality Program - Audits

- Study/Audit Timeline
- Protocol Template
  - Introduction
  - Purpose
  - Description of Study
    - Sample size
    - Study population
  - Audit Notification
  - Audit Procedures
  - Reconciliation Procedures
  - Data Analysis plan
  - Feedback plan
  - Recommendations
- Protocol Review
The NPCR–AERRO scope diagram shown above is a simple flow diagram that identifies hospital and central registry data sources in a ranked order, based on the quantity of useful data that are available and reported to the central cancer registry.
Completeness

• Casefinding is not just a Discharge Diagnosis Index

• Pathology Casefinding is Critical because HIM misses 10% or more of all cases because they don’t have info available at time of discharge or for ambulatory surgeries

• FCDS will soon be conducting e-path completeness audits to ensure all cases are reported in addition to AHCA and Mortality and FAPTP as well as complete tx.

• Too many cases are being missed from pathology.
• Too much hospital-based treatment is not reported.
Complete Casefinding

- Pathology Reports – up to 10% of cases missed by HIM
- Other Lab Reports – bone marrow, autopsy, addenda, etc.
- In-Patient Discharge Diagnosis Index
- Out-Patient Services Diagnosis/Procedures Index
- Other Ambulatory Patient Services
  - Specialty Clinics – melanoma, head & neck, GI, GYN, etc.
  - Breast Diagnostic/Treatment Center
  - Diagnostic Imaging Center
  - Radiation Oncology Center
  - Medical Oncology Infusion Center
- ICD-9-CM Required Codes
- ICD-10-CM Required Codes
Audits to Assess Completeness

The extent to which all required cases have been reported to FCDS. FCDS file completeness is assessed using:

- ACHA (covers 100% audit of all In-Patient and Out-Patient Visits)
- FAPTP – Florida Association of Pediatric Tumor Programs
- Breast Cancer Early Detection Program Match
- Interstate Data Exchange
- Annual Death Clearance
- Field Casefinding Audits
- E-Path Matching
- Other Linkages
- NDI

NPCR Requires FCDS to be 90% complete 12 months after close of dx year – from all report sources

NPCR Requires FCDS to be 95% complete 24 months after close of dx year – from all report sources
Audits to Assess Completeness

Casefinding Audits

• QC staff will periodically perform on-site review of casefinding procedures and casefinding sources within each facility. (Medical Records, e-path, clinics, other).

• If any case is found to meet the cancer reporting requirements outlined in Section I, the case must be abstracted and reported to FCDS.

• For any case found that does not meet the cancer reporting requirements outlined in Section I, an explanation must be submitted to FCDS detailing the reason it will not be reported.

• Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.

• When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.

• FCDS will add matching and follow-back of e-path records to facility submissions in the future as an annual routine Casefinding Audit and will also be used for Data Validation comparing text-to-code assignments against the original e-path report.
AHCA Clearance and Casefinding Audit

- AHCA is the Agency for Health Care Administration with a primary function of tracking ALL patient encounters (diagnosis, treatment, billing, etc.) for nearly all healthcare facilities in the state of Florida.

- ANNUAL Match the FCDS Master File to the Florida AHCA files for both inpatient and outpatient/ambulatory patient encounters. All Facilities.

- FCDS provides each reporting facility with a list of Unmatched AHCA Cases (cases that appear in the AHCA files but have no matching record in the FCDS Master File) and available in FCDS IDEA on the FCDS website.

- Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.

- When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.

Audits to Assess Completeness
Death Clearance and Casefinding Audit

Many registrars do not recognize Annual Death Clearance as a casefinding audit, but it is. The Florida Bureau of Vital Statistics tracks every birth and death in the state of Florida and has for many years.

FCDS Conducts an ANNUAL matching of the entire FCDS Master File (3.5 million records) to the annual Vital Statistics Mortality File.

Any “cancer-related” Florida deaths without a matched record in the FCDS Master File are followed back to the hospital or physician authorizing the VS report to determine why the facility/physician did not submit the case.

Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.

When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.

Audits to Assess Completeness
FAPTP Clearance and Casefinding Audit

- Many registrars do not recognize this as an audit, but it is. The Florida Association of Pediatric Tumor Programs (FAPTP) captures data on pediatric tumors diagnosed and/or treated within their consortium of hospitals and cancer programs.

- FCDS Conducts an ANNUAL matching of the entire FCDS Masterfile (3.5 million records) to the annual FAPTP File

- Any records found not to match the FCDS Masterfile but having been seen in the facility are followed back to determine why they did not send the case.

- Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.

- When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.

Audits to Assess Completeness
Audits to Assess Timeliness

Timeliness is determined by measuring how long it takes from the time a patient walks through the door of your facility for a diagnosis to be made, treatment plan to be created and initiated, the case is abstracted, the case is uploaded to FCDS without error and more.

- **Standard Set by NAACCR, CDC/NPCR, ACoS/CoC, FCDS:**
  - 95% cases submitted within 6 months from date of service.
  - 100% of cases must be reported by June 30th.

- **FCDS Annual June 30th Deadline**
- **FCDS Quarterly Status Reports**

- **Once-A-Year Submissions DO NOT Meet Reporting Requirements**
  - Monthly Reporting is preferred so you stay current
  - Quarterly Reporting for Facilities with >500 cases/year
2014 Change to CoC Standard 5.2

- CoC Standard 5.2 was the 6-month Abstracting Requirement
- 2014 Standard 5.2 was Changed to RQRS Reporting AND On-Time Completed Case Reporting to NCDB in January
- **NO CHANGE IN FCDS ANNUAL JUNE 30 DEADLINE**
- **NO CHANGE IN FCDS 6-MONTH REPORTING**
- **SUBMIT COMPLETED CASE TO FCDS**
- FCDS not yet set up to receive Update/Modify Records
Audits to Assess Accuracy/Data Quality

The extent to which the data submitted has been correctly and consistently coded and reflects the clinical, diagnostic, descriptive, decisions for treatment planning, or other information contained in the medical record.

- FCDS Abstractor Code Required for Each Abstractor
- FCDS Abstractor Code Annual Renewal
- Policy for Data Submission
- Standard FCDS EDITS Metafile
- Text Documentation Requirements
- Case Corrections / Forces (Edit Override)
- QC Visual Editing – A 3-step Process
- Audits for Completeness
- Audits for Accuracy
- External Audits
- Data Use
Audits to Assess Accuracy/Data Quality

**FCDS Validation/Re-abSTRACTing Audits**

- The FCDS Quality Control staff and/or outside contract agents working on behalf of FCDS perform on-site or remote access source record review of abstracting and coding by re-abbstracting cases from original source paper or electronic medical records for cases previously submitted to FCDS.

- Re-abbstracting/Validation Audits assess the consistency in interpretation, instruction and use of standard data definitions, coding rules and guidelines, reference resources, and policies and procedures; and serve to identify areas that may require further education and training.

- Reconciliation of Re-abbstracting Audit Inconsistencies between original data and audited data is an Important Component: Key data items are evaluated and any discrepancy noted between the auditor’s findings and the original abstract findings are returned to the facility for reconciliation.

- 2014 – Intensive Visual Editing Audit and E-Path Data Validation
External Audits

CDC NPCR Audits (Casefinding/Re-Abstracting/Consolidation)

• The CDC NPCR staff and/or outside contract agents working on behalf of NPCR perform on-site and/or remote review of FCDS Policy and Procedures Manuals, routine operations, standard FCDS EDITS, QC Review, Audits, and Record Consolidation operations and outcomes.

• The CDC NPCR staff and/or outside contract agents working on behalf of NPCR perform on-site and/or remote audits of sources records as well as consolidated FCDS Master File records by reviewing paper and/or electronic medical records, FCDS Master File records, and other available source records on cases previously submitted to FCDS.

• Reconciliation of differences between original data and audited data is an important component: Key data items are evaluated and any discrepancy noted between the auditor’s findings and the original abstract findings or consolidation findings are returned to FCDS for reconciliation.
FCDS Data Quality Reports

- FCDS Upload EDIT Discrepancy Journal
- FCDS Quarterly Status Report
- FCDS Data Quality Indicator Report
- FCDS Re-Abstracting Study Report
- NPCR Data Quality Indicator Reports
- NAACCR Certification
## Discrepancy Analysis Detail for Batch

### Note:
Warnings are not counted as failed edits

<table>
<thead>
<tr>
<th># Failures</th>
<th>Percentage</th>
<th>Edit #</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>3.30%</td>
<td>197</td>
<td>Invalid characters in City of Diagnosis</td>
</tr>
<tr>
<td>4</td>
<td>3.30%</td>
<td>249</td>
<td>Invalid Characters exist in City Current</td>
</tr>
<tr>
<td>33</td>
<td>27.73%</td>
<td>450</td>
<td>The zip code, county, and/or city name spelling combination is not valid according to the United States Postal Service (USPS).</td>
</tr>
<tr>
<td>1</td>
<td>0.84%</td>
<td>457</td>
<td>The format of the Address Current is not a valid USPS address</td>
</tr>
<tr>
<td>1</td>
<td>0.84%</td>
<td>458</td>
<td>The format of the Address at DX is not a valid USPS address</td>
</tr>
<tr>
<td>2</td>
<td>1.66%</td>
<td>874</td>
<td>Addr at DX—Postal code is invalid for FL</td>
</tr>
<tr>
<td>2</td>
<td>1.66%</td>
<td>832</td>
<td>Addr Current—Postal code is invalid for FL</td>
</tr>
<tr>
<td>8</td>
<td>6.72%</td>
<td>883</td>
<td>Addr Current—Postal code must not = 99999</td>
</tr>
<tr>
<td>12</td>
<td>10.06%</td>
<td>887</td>
<td>Addr at DX—City is not a valid FL city name</td>
</tr>
<tr>
<td>2</td>
<td>1.66%</td>
<td>894</td>
<td>If Addr Current—State not = XX, YY, ZZ, AA, AP, AE or Canada, Addr Current—City cannot = UNKNOWN</td>
</tr>
<tr>
<td>12</td>
<td>10.06%</td>
<td>895</td>
<td>Addr Current—City is not a valid FL city name</td>
</tr>
<tr>
<td>1</td>
<td>0.84%</td>
<td>897</td>
<td>If Addr Current—State = FL, County—Current cannot = 999</td>
</tr>
<tr>
<td>4</td>
<td>3.30%</td>
<td>900</td>
<td>If Addr Current—State not = XX, YY, AA, AP, AE or Canada, Addr Current—NoStreet cannot = UNKNOWN</td>
</tr>
<tr>
<td>33</td>
<td>27.73%</td>
<td>901</td>
<td>The Addr Current—City, County—Current, and/or Addr Current—Postal Code combination is not valid according to the United States Postal Service (USPS).</td>
</tr>
</tbody>
</table>
FCDS Edit Check Discrepancy Journal

Discrepancy Journal
11/15/2012 3:11:24 PM
Page: 6 of 9

Error 377
Force: Y
Patient has multiple primaries and Dx Confirmation is not equal to 1, 2, 4 or 5 on all Sequences
Discrepancy Data: Inter-Record Edit (PCDS)
Discrepancy Description: For Discrepancy within Patient both must equal 1, 2, 4 or 5.

Error 332
Force: Y
Patient has multiple primaries and Dx Confirmation is not equal to 1, 2, 4 or 5 on all Sequences
Discrepancy Data: Inter-Record Edit (PCDS)
Discrepancy Description: For Sequence Number-Hospital = 02, Dx Confirmation should not be 7.
Primary Site (560) (C349)
Dx Confirmation (562) (7)
Sequence Number-Hospital (760) (02)
Vendor Name (1936) [METRIQ2.40]

Error 92
Force: N
Sequence 02 being processed without a Sequence 01 in pending file or 00 or 01 in master file
Discrepancy Data: Inter-Record Edit (PCDS)

Error 357
Force: Y
Histologic Type ICD-03/Behavior Code ICD-03 not valid with Primary Site
Discrepancy Data: Primary Site, Morphology-Type, Histology-ICD03 (ENN_IPFIS)
Histologic Type ICD-03 (8507)/Behavior Code ICD-03 (1) not valid with Primary Site (C508)
Primary Site (560) (C508)
Histologic Type ICD-03 (8507) (5507)
Behavior Code ICD-03 (154) (1)
Over-Ride Site/Type (1906) [BLANK]

Error 245
Force: Y
Sequence Greater Than Zero with All-Defined Primary Site (C76.7) or C82.9 or All-Defined Lymphoma or All-Defined Leukemia
Discrepancy Data: Seq Num-Disp, Primary Site, Morphology ICD-03 (CONS)
K:0245: Site:CMS09 & Hist:8140 & Seq Num (02) is greater than 00 - please review
Sequence Number-Hospital (760) (02)
Primary Site (560) (C509)
Histologic Type ICD-03 (8507) (5507)
Behavior Code ICD-03 (154) (1)
Over-Ride Code/Seq (1904) [BLANK]

Error 961
Force: Y
Breast-Prostate - Radiation Rx Date must be less than 365 days after Diagnosis Date
Discrepancy Data: Rx Date-Add, Primary Site, Date EX-365 (PCDS)
K:0646: If Site:CMS09, Rx Date-Radiation (Y:2008 M:12 D:02) must be less than 365 days after Date of Diagnosis (Y:2007 M:10 D:29)
Primary Site (560) (C509)
Date of Diagnosis (530) (2007 M:10 D:29)
Rx Date-Radiation (1686) (Y:2008 M:12 D:02)

Error 163
Force: Y
Breast-Prostate - Hormone Rx Date must be less than 365 days after Diagnosis Date

Prepared for STEVE PEACE on 11/15/2012 3:11:24 PM
6 of 9
Florida Cancer Data System
Quarterly Cancer Case Reporting Status Report

This Quarterly Cancer Case Reporting Status Report is divided into two sections: a Quarterly Activity Summary and an Annual Case Submission Summary. This report is used as a preliminary indication of the completeness, timeliness, and quality of your data.

Quarterly Activity Summary
The Quarterly Activity Summary reflects the file activity and the cases submitted by your facility for the time period specified above.

New Data Submitted:
- Total number of cases electronically submitted for this quarter
- Total number of good cases: (cases requiring no changes)
- Total number of forced cases: (exceptional cases requiring overrides of standard data edits following validation of the data submitted)

File Activity:
- Total number of deleted cases: (cases deleted due to duplicate record submission; cases that do not meet the FCDS reporting requirements; cases diagnosed prior to the FCDS 1983 reference date)
- Total number of cases in the pending file: (cases that failed one or more standard data edits during this and any previous quarters and remain in the pending file awaiting data validation)

Annual Case Submission Summary
The Annual Case Summary reflects all cases submitted by your facility for the past four years. The fifth year displayed is the current reporting year. A two-year average (excluding current year data) is the base from which the Expected Compliance Percentage is calculated.

<table>
<thead>
<tr>
<th>Admission Year</th>
<th>Case Count</th>
<th>Average # Cases Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td></td>
<td>% Complete for</td>
</tr>
<tr>
<td>2001</td>
<td></td>
<td>Recurring Year</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Actual</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Expected</td>
</tr>
</tbody>
</table>

Please review this report in detail. If you have any questions or would like additional information please call your Field Coordinator at (503) 241-4600. Thank you for your cooperation in providing timely and quality data to the FCDS.
## FCDS Data Quality Indicator Report

### Florida Cancer Data System - Facility Data Quality Indicator Report (DQIR) for 2010

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Goals</strong></td>
<td><strong>Florida</strong></td>
<td><strong>Facilities</strong></td>
<td><strong>Florida</strong></td>
<td><strong>Facilities</strong></td>
<td><strong>Florida</strong></td>
<td><strong>Facilities</strong></td>
</tr>
<tr>
<td><strong>0%</strong></td>
<td>0.000</td>
<td>0.002</td>
<td>0.000</td>
<td>0.035</td>
<td>0.250</td>
<td>0.046</td>
</tr>
<tr>
<td><strong>&lt; 1%</strong></td>
<td>1.707</td>
<td>1.088</td>
<td>0.959</td>
<td>0.956</td>
<td>4.120</td>
<td>0.839</td>
</tr>
<tr>
<td><strong>&lt; 2%</strong></td>
<td>1.031</td>
<td>0.839</td>
<td>1.450</td>
<td>1.364</td>
<td>6.165</td>
<td>1.129</td>
</tr>
<tr>
<td><strong>&lt; 3%</strong></td>
<td>0.703</td>
<td>0.508</td>
<td>1.559</td>
<td>0.797</td>
<td>3.246</td>
<td>0.967</td>
</tr>
<tr>
<td><strong>&lt; 5%</strong></td>
<td>0.300</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td><strong>&lt; 10%</strong></td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td><strong>&lt; 20%</strong></td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td><strong>&lt; 30%</strong></td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td><strong>&lt; 50%</strong></td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td><strong>&lt; 100%</strong></td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>

**Notes:**

- Analytic cases extracted 3/13/2015.
- **Percentage based on analytic cases of Florida residents at time of DK only.**
- **Percentage according to FCDS (class of case: 0 - 22 or 54 - 62)**
- **Percentage based on analytic cases of Florida residents at time of DK only.**
FCDS Re-Abstracting Audit Report

• **Major Difference**
  • Affects incidence counts
  • Affects research
  • Examples: diagnosis year, primary site, sex

• **Minor Difference**
  • Does not affect incidence counts
  • Examples: quadrant of breast, type of resection

• **Unknown-to-Known**
  • Valid data found but initially coded as unknown
  • Difference depends on data item
# FCDS Re-Abstracting Audit Report

## 7/13/2012 9:30:39 AM

**Facility Completed:**

**FCDS Completed:**

### Demographic

<table>
<thead>
<tr>
<th>Minor Discrepancy</th>
<th>Major Discrepancy</th>
<th>Total Discrepancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (n=15)</td>
<td>Count (n=10)</td>
<td>Count (n=15)</td>
</tr>
</tbody>
</table>

- **Admit Date**
  - 1: 6.67
  - 1: 6.67

- **SSN**
  - 1: 6.67
  - 1: 6.67

- **Race**
  - Sex:
    - Male: 13.33
    - Female: 13.33

- **Ethnicity**
  - White: 12.33
  - Black: 12.33

### Address

<table>
<thead>
<tr>
<th>Minor Discrepancy</th>
<th>Major Discrepancy</th>
<th>Total Discrepancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (n=15)</td>
<td>Count (n=10)</td>
<td>Count (n=15)</td>
</tr>
</tbody>
</table>

- **Any Address**
  - 1: 6.67
  - 1: 6.67

### Case

<table>
<thead>
<tr>
<th>Minor Discrepancy</th>
<th>Major Discrepancy</th>
<th>Total Discrepancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (n=15)</td>
<td>Count (n=10)</td>
<td>Count (n=15)</td>
</tr>
</tbody>
</table>

- **Date of Birth**
  - 1: 6.67
  - 1: 6.67

### Treatment

<table>
<thead>
<tr>
<th>Minor Discrepancy</th>
<th>Major Discrepancy</th>
<th>Total Discrepancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (n=15)</td>
<td>Count (n=10)</td>
<td>Count (n=15)</td>
</tr>
</tbody>
</table>

- **Surgical**
  - 1: 6.67
  - 1: 6.67

### Follow-Up

<table>
<thead>
<tr>
<th>Minor Discrepancy</th>
<th>Major Discrepancy</th>
<th>Total Discrepancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (n=15)</td>
<td>Count (n=10)</td>
<td>Count (n=15)</td>
</tr>
</tbody>
</table>

- **Vital Status**
  - 1: 6.67
  - 1: 6.67

### Total Master File Records

15
NPCR Data Quality Reports
NPCR Data Quality Reports

2013 - Standard Status Report (SSR1)
National Program of Cancer Registries
Cancer Surveillance System
(National Data Quality)

Florida

Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People
## NPCR Data Quality Reports

### Report on Quality, Completeness and Timeliness of Data

<table>
<thead>
<tr>
<th>NPCR Standards Grouping</th>
<th>Diagnosis Year**</th>
<th>Percent Completeness Adjusted for Duplicates*</th>
<th>Unresolved Duplicate Rates (per 1,000)</th>
<th>Percent Death Certificate Only</th>
<th>Percent Missing or Unknown Core Data Elements</th>
<th>Percent Passing Core Single and Inter-field Edits</th>
<th>Percent Passing Core Inter-record Edits***</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Data Quality</td>
<td>2010</td>
<td>95.14</td>
<td>0.00</td>
<td>1.93</td>
<td>0.00 0.03 0.78 0.00</td>
<td>100.00</td>
<td>100.00</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>98.66</td>
<td>0.00</td>
<td>1.97</td>
<td>0.00 0.03 0.73 0.00</td>
<td>100.00</td>
<td>100.00</td>
</tr>
<tr>
<td></td>
<td>2008</td>
<td>102.04</td>
<td>0.00</td>
<td>2.63</td>
<td>0.00 0.07 0.79 0.00</td>
<td>100.00</td>
<td>100.00</td>
</tr>
<tr>
<td></td>
<td>2007</td>
<td>100.02</td>
<td>0.00</td>
<td>2.34</td>
<td>0.00 0.06 0.78 0.00</td>
<td>100.00</td>
<td>100.00</td>
</tr>
<tr>
<td></td>
<td>2006</td>
<td>99.34</td>
<td>0.00</td>
<td>2.47</td>
<td>0.00 0.04 0.73 0.00</td>
<td>100.00</td>
<td>100.00</td>
</tr>
</tbody>
</table>

### STANDARD

<table>
<thead>
<tr>
<th>Standard</th>
<th>Percent Completeness</th>
<th>&lt;=1</th>
<th>&lt;=3</th>
<th>&lt;=2</th>
<th>&lt;=3</th>
<th>&lt;=5</th>
<th>N/A</th>
<th>N/A</th>
<th>99.00</th>
<th>99.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Data Quality Standard</td>
<td>95.00</td>
<td>&lt;=1</td>
<td>&lt;=3</td>
<td>&lt;=2</td>
<td>&lt;=3</td>
<td>&lt;=5</td>
<td>N/A</td>
<td>N/A</td>
<td>99.00</td>
<td>99.00</td>
</tr>
<tr>
<td>USCS Publication Standard</td>
<td>90.00</td>
<td>N/A</td>
<td>&lt;=5</td>
<td>&lt;=3</td>
<td>&lt;=5</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>97.00</td>
<td>97.00</td>
</tr>
<tr>
<td>Measurement Error****</td>
<td>-1.0</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### NPCR Data Quality Reports

#### 2010 Dx Year

<table>
<thead>
<tr>
<th>Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Incident Cases</strong></td>
</tr>
<tr>
<td><strong>Race Proportional Completeness,</strong> Adjusted for Reference Mortality</td>
</tr>
<tr>
<td><strong>%Unresolved Duplicates</strong></td>
</tr>
</tbody>
</table>

* 0.00 indicates all duplicates are resolved.

#### 2009 Dx Year

<table>
<thead>
<tr>
<th>Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Incident Cases</strong></td>
</tr>
<tr>
<td><strong>Race Proportional Completeness,</strong> Adjusted for Reference Mortality</td>
</tr>
<tr>
<td><strong>%Unresolved Duplicates</strong></td>
</tr>
</tbody>
</table>

* 0.00 indicates all duplicates are resolved.
NPCR Data Quality Reports

2013 - Submission Summary Report (SSR2)
National Program of Cancer Registries
Cancer Surveillance System
(National Data Quality)

Florida

Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People
### NPCR Data Quality Reports

**Florida**

<table>
<thead>
<tr>
<th>Diagnosis Year</th>
<th>Records Received</th>
<th>Non-reportable Records</th>
<th>Reportable Records</th>
<th>Invasive Records*</th>
<th>In Situ Records</th>
<th>Benign Brain Records</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>112037</td>
<td>0</td>
<td>112037</td>
<td>102166</td>
<td>6540</td>
<td>3331</td>
</tr>
<tr>
<td>2009</td>
<td>117564</td>
<td>0</td>
<td>117564</td>
<td>106772</td>
<td>7249</td>
<td>3543</td>
</tr>
<tr>
<td>2008</td>
<td>119027</td>
<td>0</td>
<td>119027</td>
<td>108297</td>
<td>7345</td>
<td>3385</td>
</tr>
<tr>
<td>2007</td>
<td>116930</td>
<td>0</td>
<td>116930</td>
<td>105427</td>
<td>7313</td>
<td>3190</td>
</tr>
<tr>
<td>2006</td>
<td>114304</td>
<td>0</td>
<td>114304</td>
<td>104404</td>
<td>6606</td>
<td>3294</td>
</tr>
<tr>
<td>&lt;= 2005 **</td>
<td>1147891</td>
<td>0</td>
<td>1147891</td>
<td>1085770</td>
<td>55807</td>
<td>6314</td>
</tr>
</tbody>
</table>

Prior to NPCR Reference Year

<table>
<thead>
<tr>
<th></th>
<th>Records Received</th>
<th>Non-reportable Records</th>
<th>Reportable Records</th>
<th>Invasive Records*</th>
<th>In Situ Records</th>
<th>Benign Brain Records</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>1727753</td>
<td>0</td>
<td>1727753</td>
<td>1613836</td>
<td>90860</td>
<td>23057</td>
</tr>
</tbody>
</table>

* Invasive records include in situ bladder.

** Includes all submitted records from the NPCR reference year through 2005.
# NPCR Data Quality Reports

## Florida

### Table 3: Percentage of Over-Ride Flagged Fields — Grouped by Edit Name and Diagnosis Year

<table>
<thead>
<tr>
<th>Diagnosis Year</th>
<th>Age, Primary Site, Morphology (NAACCR IF16)</th>
<th>Diagnostic Confirm, Seq Num-Central (SEER IF23)</th>
<th>Site/Histology, Laterality/Sequence Number (IRIS)</th>
<th>Primary Site, Morphology-Type Check (SEER IF26)</th>
<th>1 = Morphology-Type &amp; Behavior (SEER MORPH)</th>
<th>2 = Diagnostic Confirmation, Behavior Code (SEER IF51)</th>
<th>3 = Both 1 and 2 Apply</th>
<th>Type of Report Source (DC), Seq Num-Central (SEER IF22)</th>
<th>Seq Num-Central, Primary Site, Morphology Confirmation Histology Type (SEER IF48)</th>
<th>Primary Site, Behavior Code (SEER IF59)</th>
<th>Laterality, Primary Site, Morphology Confirmation (SEER IF42)</th>
<th>Percentage of Records with Over-Ride Flags</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>0.12</td>
<td>1.26</td>
<td>0.27</td>
<td>0.72</td>
<td>0.76</td>
<td>0.00</td>
<td>0.00</td>
<td>0.03</td>
<td>0.83</td>
<td>0.00</td>
<td>0.01</td>
<td>4.00</td>
</tr>
<tr>
<td>2009</td>
<td>0.09</td>
<td>1.02</td>
<td>0.22</td>
<td>0.69</td>
<td>0.69</td>
<td>0.00</td>
<td>0.00</td>
<td>0.02</td>
<td>0.65</td>
<td>0.00</td>
<td>0.00</td>
<td>3.59</td>
</tr>
<tr>
<td>2008</td>
<td>0.11</td>
<td>0.54</td>
<td>0.26</td>
<td>0.65</td>
<td>0.57</td>
<td>0.00</td>
<td>0.00</td>
<td>0.04</td>
<td>0.75</td>
<td>0.00</td>
<td>0.00</td>
<td>3.32</td>
</tr>
<tr>
<td>2007</td>
<td>0.11</td>
<td>0.89</td>
<td>0.30</td>
<td>0.67</td>
<td>0.19</td>
<td>0.00</td>
<td>0.00</td>
<td>0.03</td>
<td>0.78</td>
<td>0.00</td>
<td>0.00</td>
<td>2.97</td>
</tr>
<tr>
<td>2006</td>
<td>0.10</td>
<td>0.66</td>
<td>0.25</td>
<td>0.92</td>
<td>0.12</td>
<td>0.00</td>
<td>0.00</td>
<td>0.05</td>
<td>0.76</td>
<td>0.01</td>
<td>0.00</td>
<td>3.67</td>
</tr>
</tbody>
</table>

### SEER OVER-RIDE FLAG QUALITY MEASURES**

- Age/Primary Site/Morphology: 0.16
- Diagnostic Confirm, Seq Num-Central: 0.93
- Site/Histology, Laterality/Sequence Number: 0.38
- Primary Site, Morphology-Type Check: 1.32
- 1 = Morphology-Type & Behavior: 0.23
- 2 = Diagnostic Confirmation, Behavior Code: 0.02
- Both 1 and 2 Apply: 0.02
- Type of Report Source: 0.12
- Seq Num-Central, Primary Site, Morphology Confirmation Histology Type: 0.40
- Primary Site, Behavior Code: 0.04
- Laterality, Primary Site, Morphology Confirmation: 0.06
- Percentage of Records with Over-Ride Flags: 0.07
NPCR Data Quality Reports

2013 - Data Quality Indicator Report (DQI)
National Program of Cancer Registries
Cancer Surveillance System
(National Data Quality)

Florida

Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People
### NPCR Data Quality Reports

#### Table 1: Core Cancer Surveillance Data

<table>
<thead>
<tr>
<th>Data Quality Indicator \ Diagnosis Year</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>NPCR Median(Range)</th>
<th>SEER Median(Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>County at Diagnosis [90]</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00(0.00 - 0.00)</td>
<td>0.00(0.00 - 0.00)</td>
</tr>
<tr>
<td>Unknown (999)</td>
<td>0.00</td>
<td>0.01</td>
<td>0.02</td>
<td>0.02</td>
<td>0.04</td>
<td>0.0(0.00 - 0.00)</td>
<td>0.02(0.00 - 1.06)</td>
</tr>
<tr>
<td>County Recode (000)</td>
<td>0.00</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02</td>
<td>0.04</td>
<td>0.0(0.00 - 0.00)</td>
<td>0.02(0.00 - 1.06)</td>
</tr>
<tr>
<td>Spanish/Hispanic Origin [190]</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00(0.00 - 0.00)</td>
<td>0.00(0.00 - 0.00)</td>
</tr>
<tr>
<td>Unknown (9)</td>
<td>0.54</td>
<td>2.86</td>
<td>2.63</td>
<td>2.43</td>
<td>3.07</td>
<td>0.74(23.81 - 23.93)</td>
<td>2.76(0.00 - 30.81)</td>
</tr>
<tr>
<td>NHA Derived Hisp Origin [191]</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00(0.00 - 0.00)</td>
<td>0.00(0.00 - 0.00)</td>
</tr>
<tr>
<td>Birthdate [240]</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00(0.00 - 0.04)</td>
<td>0.00(0.00 - 0.07)</td>
</tr>
<tr>
<td>Birthplace [250]</td>
<td>0.08</td>
<td>0.03</td>
<td>0.03</td>
<td>0.04</td>
<td>0.03</td>
<td>0.03(0.00 - 0.03)</td>
<td>0.00(0.00 - 0.03)</td>
</tr>
<tr>
<td><strong>Tumor Characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two or more (01 - 35)</td>
<td>27.97</td>
<td>25.59</td>
<td>25.78</td>
<td>25.37</td>
<td>25.26</td>
<td>25.26(14.31 - 26.71)</td>
<td>25.61(13.88 - 26.81)</td>
</tr>
<tr>
<td>Date of Diagnosis [390]</td>
<td>0.04</td>
<td>0.24</td>
<td>0.24</td>
<td>0.24</td>
<td>0.24</td>
<td>0.24(0.00 - 2.24)</td>
<td>0.24(0.00 - 2.24)</td>
</tr>
<tr>
<td>Month (blank)</td>
<td>0.04</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03(0.00 - 0.04)</td>
<td>0.03(0.00 - 0.04)</td>
</tr>
<tr>
<td>Topography [400]</td>
<td>0.03</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01(0.00 - 0.17)</td>
<td>0.01(0.00 - 0.17)</td>
</tr>
<tr>
<td>Other Tumor Sites (C76.0 - C76.8)</td>
<td>0.03</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01(0.00 - 0.17)</td>
<td>0.01(0.00 - 0.17)</td>
</tr>
<tr>
<td>Unknown Primary Site (C80.9)</td>
<td>0.33</td>
<td>0.34</td>
<td>0.34</td>
<td>0.34</td>
<td>0.34</td>
<td>0.34(0.00 - 0.18)</td>
<td>0.34(0.00 - 0.18)</td>
</tr>
<tr>
<td>Non-specific Neoplasms (8000 - 8005)</td>
<td>5.07</td>
<td>3.79</td>
<td>3.79</td>
<td>3.79</td>
<td>3.79</td>
<td>3.79(1.75 - 17.16)</td>
<td>3.79(1.75 - 17.16)</td>
</tr>
<tr>
<td>Diagnostic Confirmation [460] excludes DCO</td>
<td>3.15</td>
<td>3.32</td>
<td>3.32</td>
<td>3.32</td>
<td>3.32</td>
<td>3.32(0.00 - 6.97)</td>
<td>3.32(0.00 - 6.97)</td>
</tr>
<tr>
<td>Tumor Miscellaneous</td>
<td>33.31</td>
<td>32.88</td>
<td>32.88</td>
<td>32.88</td>
<td>32.88</td>
<td>32.88(23.78 - 37.15)</td>
<td>32.88(23.78 - 37.15)</td>
</tr>
<tr>
<td>Grade [440]</td>
<td>0.17</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13(0.00 - 0.18)</td>
<td>0.13(0.00 - 0.18)</td>
</tr>
<tr>
<td>Laterality [415]</td>
<td>0.17</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13(0.00 - 0.18)</td>
<td>0.13(0.00 - 0.18)</td>
</tr>
<tr>
<td>Only 1 side and side NOS (3)</td>
<td>0.17</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13(0.00 - 0.18)</td>
<td>0.13(0.00 - 0.18)</td>
</tr>
<tr>
<td>Unknown (9, blank)</td>
<td>2.68</td>
<td>2.52</td>
<td>2.52</td>
<td>2.52</td>
<td>2.52</td>
<td>2.52(1.18 - 4.87)</td>
<td>2.52(1.18 - 4.87)</td>
</tr>
</tbody>
</table>
### NPCR Data Quality Reports

#### Table 1: Core Cancer Surveillance Data

<table>
<thead>
<tr>
<th>Data Quality Indicator \ Diagnosis Year</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2006-2010</th>
<th>SEER Median/Range**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>CS Mess at DX [2850]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Unknown (99)</td>
<td>7.87</td>
<td>6.34</td>
<td>20.58</td>
<td>6.49</td>
<td>6.90</td>
<td>16.00</td>
<td>3.60/10.22</td>
</tr>
<tr>
<td>Derived Summary Stage 2000 [3020]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown/Unstaged (9)</td>
<td>8.09</td>
<td>6.94</td>
<td>12.20</td>
<td>7.37</td>
<td>4.83</td>
<td>9.79/13.98</td>
<td>4.47/13.20</td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First Course Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ Surg Prim Site [1290]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Surgery, NOS (90)</td>
<td>0.94</td>
<td>0.48</td>
<td>3.68</td>
<td>0.79</td>
<td>0.40</td>
<td>3.41/6.56</td>
<td>0.63/2.79</td>
</tr>
<tr>
<td>Unknown (99)</td>
<td>3.45</td>
<td>3.54</td>
<td>12.86</td>
<td>2.96</td>
<td>3.23</td>
<td>13.99/19.66</td>
<td>1.82/5.93</td>
</tr>
<tr>
<td>Blank and Unknown Combined</td>
<td>3.45</td>
<td>3.54</td>
<td>12.86</td>
<td>2.96</td>
<td>3.23</td>
<td>13.99/19.66</td>
<td>1.82/5.93</td>
</tr>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ Scope Reg LN Sur [1292]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Unknown (9)</td>
<td>16.87</td>
<td>16.76</td>
<td>24.01</td>
<td>16.50</td>
<td>16.26</td>
<td>24.21/27.24</td>
<td>25.87/32.53</td>
</tr>
<tr>
<td>Blank and Unknown Combined</td>
<td>16.87</td>
<td>16.76</td>
<td>24.01</td>
<td>16.50</td>
<td>16.26</td>
<td>24.21/27.24</td>
<td>25.87/32.53</td>
</tr>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ Surg Oth Reg/Dis [1294]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Unknown (9)</td>
<td>11.24</td>
<td>8.95</td>
<td>14.66</td>
<td>10.94</td>
<td>11.06</td>
<td>14.43/16.94</td>
<td>1.32/5.93</td>
</tr>
<tr>
<td>Blank and Unknown Combined</td>
<td>11.24</td>
<td>8.95</td>
<td>14.66</td>
<td>10.94</td>
<td>11.06</td>
<td>14.43/16.94</td>
<td>1.32/5.93</td>
</tr>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reason for No Surgery [1340]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Unknown (9)</td>
<td>3.85</td>
<td>7.18</td>
<td>20.67</td>
<td>3.35</td>
<td>7.10</td>
<td>18.84/26.78</td>
<td>1.82/5.93</td>
</tr>
<tr>
<td>Blank and Unknown Combined</td>
<td>3.85</td>
<td>7.18</td>
<td>20.67</td>
<td>3.35</td>
<td>7.10</td>
<td>18.84/26.78</td>
<td>1.82/5.93</td>
</tr>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ Radiation [1380]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Unknown (9)</td>
<td>3.44</td>
<td>2.69</td>
<td>17.07</td>
<td>3.17</td>
<td>2.62</td>
<td>14.25/16.84</td>
<td>2.30/10.65</td>
</tr>
<tr>
<td>Blank and Unknown Combined</td>
<td>3.44</td>
<td>3.11</td>
<td>15.00</td>
<td>3.17</td>
<td>3.70</td>
<td>14.92/16.84</td>
<td>2.30/10.65</td>
</tr>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ Surg/Rad Seq [1380]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Unknown (9)</td>
<td>0.24</td>
<td>0.22</td>
<td>0.03</td>
<td>0.19</td>
<td>0.19</td>
<td>0.06/0.59</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td>Blank and Unknown Combined</td>
<td>0.24</td>
<td>0.22</td>
<td>0.03</td>
<td>0.19</td>
<td>0.19</td>
<td>0.06/0.59</td>
<td>0.00/0.00</td>
</tr>
<tr>
<td><strong>NPCR Median/Range</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ Chemo [1390]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blank</td>
<td>5.04</td>
<td>5.69</td>
<td>49.09</td>
<td>4.33</td>
<td>5.03</td>
<td>34.97/47.86</td>
<td>N/A</td>
</tr>
<tr>
<td>Unknown (99)</td>
<td>4.33</td>
<td>4.33</td>
<td>22.13</td>
<td>2.61</td>
<td>3.33</td>
<td>21.16/26.16</td>
<td>N/A</td>
</tr>
</tbody>
</table>
NAACCR Registry Certification

[Map of Florida with NAACCR Gold Certification logo]
Other – Reinforcement

✓ Monitor Compliance with Feedback to Registrar and Administration

✓ Data Quality and Timeliness Reports to Administration

✓ Targeted Education and Training Programs
  • FCDS Annual Conference
  • FCDS Annual Series of Webcasts
    • 5 per year or as needed
    • Recorded and archived
  • FCDS On-Line Abstractor Training Course
  • Published Resources for Registrars
  • Monthly NAACCR Educational Webcast Series at 7 Locations in FL
Other – Incentives and Rewards

• Jean Byers Award including Publication of Name in Register
• Individual Abstractor Recognition Certificates
• Other Recognition – Future of Rewards
FCDS Education and Training

• New Registrar Recruitment

• **Instruction:** FCDS/National Coding Rules and Guidelines

• **Instruction:** FCDS/National Policy/Procedures

• **Re-Instruction:** Existing Rules/Procedures – Correct Problems

• **Instruction:** Changes To / New Rules/Procedures

• Continuing Education – Increase Knowledge Base

• Retention of Qualified Staff
FCDS Education and Training

- On-Line Abstracting Course for New Registrars
- FCDS Abstractor Code
- FCDS Annual Conference
- FCDS Annual Webcast Series
- NAACCR Cancer Registry Webinar Series
- NAACCR CTR Exam Prep and Review Webinar Series
- Ad Hoc Webcasts for New Programs/Policy/Procedure/Other
- FCDS Staff In-Services
- FCDS EDITS In-Services
- Personalized Instruction
## FCDS Education and Training

<table>
<thead>
<tr>
<th>NCRA CEU #</th>
<th>Date</th>
<th>Event</th>
<th>Sponsor</th>
<th>CEU Hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013-114</td>
<td>7/25/2013 - 7/26/2013</td>
<td>FCDS Annual Conference, Sunrise, FL</td>
<td>FCDS</td>
<td>8.25</td>
</tr>
</tbody>
</table>
## FCDS Education and Training

<table>
<thead>
<tr>
<th>Event</th>
<th>CEU Education Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCDS Annual Meeting</td>
<td>8-10</td>
</tr>
<tr>
<td>FCDS Webcasts</td>
<td>10-16</td>
</tr>
<tr>
<td>NAACCR Webinars</td>
<td>36</td>
</tr>
<tr>
<td>NAACCR CTR Exam Prep</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>ANNUAL TOTAL FCDS-Sponsored</strong></td>
<td><strong>60+ hours of education offered FREE each year</strong></td>
</tr>
</tbody>
</table>
Other New Education Portals

http://www.CancerRegistryEducation.org

- Live Webinars
- Learning Modules
- Online Courses
- CTR Exam Study Materials
- Online CTR Exam Practice Test
- More to Come
Other New Education Portals

Cyber Cancer Registry

Welcome to the Cyber Cancer Registry!

The Cyber Cancer Registry is an interactive tool developed by CDC's National Program of Cancer Registries (NPCR) to prepare people for a career in the cancer registry field. By working through the exercises and quizzes, you will gain practical experience in the functions of a cancer registrar in both hospitals and central registries.

For technical questions about the Cyber Cancer Registry, please contact the system administrator (cancerinfo@cdc.gov).

Casefinding Module

Casefinding Practice

Practice the exercises in this module to gain experience in the casefinding functions of a cancer registrar. You may repeat the practice exercises as many times as you like. In general, there are 20 practice exercises displayed at a time with a unique report ID number.

For this module, you may download the Screening List of ICD-9-CM Codes for Casefinding (PDF-22KB) and the Reportable Diagnoses document (PDF-35KB), which includes ambiguous terminology rules. Please use these documents in your decisions for reportability. More information is available from the References link at the top.

Casefinding Quiz

Take the Casefinding Quiz at any time and receive a certificate upon completion. You may repeat the quiz as many times as you like. However, the quiz must be completed in one session, so please allow enough time to finish.
Other New Education Portals
Other New Education Portals

https://educate.fhcrc.org/

Medical Terminology

Computer Principles

ACoS/CoC Standards

Real-Life Case Scenarios
Other New Education Portals

- Prepare for CTR exam
- Earn CEU credits free
- Train on real-life case scenarios
- Learning new coding schemes, rules, and guidelines
  - 295 Practice Cases
  - 12 Major Site Groups
  - 60+ Data Items Coded
Other New Education Portals

http://eo2.commpartners.com

Welcome to the Cancer Programs Education Portal of the American College of Surgeons. This site holds a wealth of educational opportunities for individuals involved in cancer care and work with the following organizations: the Commission on Cancer, the National Accreditation Program for Breast Centers, and the American Joint Committee on Cancer.

Need assistance logging in or navigating this site? The videos below will guide you through creating a new user account on the site and how to order and view content.
Other New Education Portals

http://moodle.med.miami.edu/server/moodle/

Florida Cancer Data System: Learning Management System

My courses

COURSE 1. FCDS Online Abstracting Basics Course
FCDS: FCDS LMS

A basic abstracting course designed to provide an understanding and the fundamentals of incidence cancer case abstracting within the state of Florida.

This course IS NOT intended to prepare a student to sit for a CTR exam. This basic course is moderately detailed and provides the student with the fundamentals of incidence abstracting and an overview of cancer registration.

The course is comprised of approximately 1,000 Powerpoint Slides with voiceovers. At the end of each section, there is an examination. Each section must be completed in order to move to the next section. At the end of the course, the student will be given a Certificate of Completion that will include the raw score for each of the examinations.

FCDS Online Abstracting Basics Course
FCDS Abstractor Code Initial Exam
FCDS Abstractor Code Renewal Exam
Other State Abstractor Code Exams
More to Come
FCDS “Future Vision”

http://jessie-emergentmediamarkets.blogspot.com
How is QC/Education Changing?

- FCDS Goals and Objectives have not changed
- FCDS will continue all reporting requirements.
- FCDS making every attempt to make any changes minimal.
- FCDS making every attempt to make any changes seamless.
- FCDS will continue to plan for upcoming changes
  - TNM, SS2000, physician reporting, and more
- FCDS will continue enforcing deadlines/reporting compliance.
- FCDS will continue to be available for technical Q&A.
How is QC/Education Changing?

• Monitoring Activities will likely be enhanced
• Feedback to Hospitals still being planned
• Some QC Activities will be cut back
  • FCDS will continue all EDITS requirements.
  • FCDS will continue to perform QC Reviews.
  • FCDS will continue to perform completeness audits with F/B.
  • FCDS will continue to perform validation audits and reconciliation.
• Some Education/Training Activities will be cut back
  • FCDS will continue to offer NAACCR Webinars.
  • FCDS will continue to offer NAACCR CTR Prep Series.
  • FCDS will continue to host an Annual Meeting.
  • FCDS will continue to host a Florida Webcast Series.
THE PERFECT DESIGNER WORKSTATION

- Hair styling and beard grooming machine
- 3 in one device, Mouse and Graphics Tablet, game controller pad
- Web cam with filters and mic with autotone for your video and podcast
- 5 Different LED Screen Sizes for responsive testing and multi-tasking
- Punching Desktop Mime Figure to represent the client, developer or IE
- Mind reader to read clients needs
- Ultra slim water proof keyboard with quick dial to your favorite food delivery outlet
- Smartphone with auto instant voice language translation for international clients

Randomly generated quotes to praise yourself:

YOU ARE GOOD!

Wireless Headphone Dock

Auto Coffee Dispensing Machine

Mini Fridge compartment

Instant PSD to HTML conversion button

Self wash toilet seat with back massage function

Customizable Photoshop Shortcuts Pedals (Alt+Shift+Ctrl+K - Saved for web version, Ctrl+Shift+Z - Undo, e.g.)

ABC! DEF GH! JKLMN OPQRSTUVWXYZ!
CURRENT FCDS QC ISSUES
Although the American College of Surgeons/Commission on Cancer does not require accredited facilities to abstract historical cases, FCDS does require the collection and reporting of certain historical cancers.

**DEFINITION:** A historical case (Class of Case 33) refers to a primary reportable neoplasm (malignant or benign/borderline brain/CNS tumors).

Patients diagnosed with any cancer during their lifetime are many times more likely to develop new cancers. It is very important for researchers to know the number and types of any and all cancers each patient has during his/her lifetime in order to effectively research and evaluate cancer incidence.
Reportable Cases - Required

Reporting Historical Cancers to FCDS – FCDS DAM

If a patient has at least one primary reportable neoplasm which is active or under treatment, all other primary reportable neoplasms the patient has ever had (active or inactive), regardless of the date of diagnosis, must be reported. Each case of cancer must be abstracted and reported separately.

Information about these previous (historical) primaries may be sketchy. The abstractor should attempt to complete an abstract with as much information as is available in the medical record.
Class of Case

The Class of Case reflects the facility’s role in managing the cancer, whether the cancer is required to be reported by CoC, and whether the case was diagnosed after the program’s Reference Date.

FCDS relies on accurate Class of Case coding

Documentation often lacking or insufficient in text

Some Registrars only want to abstract cases required by CoC

Florida Statute overrules voluntary reporting to CoC
### Class of Case

<table>
<thead>
<tr>
<th>Analytic Classes of Case</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial diagnosis at reporting facility</strong></td>
<td>00 Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere</td>
</tr>
<tr>
<td></td>
<td>10 Initial diagnosis at the reporting facility or in a staff physician’s office AND part or all of first course Treatment or a decision not to treat was at the reporting facility, NOS.</td>
</tr>
<tr>
<td></td>
<td>If it is <strong>not known</strong> that the patient actually <strong>went somewhere else</strong>, code Class of Case 10</td>
</tr>
<tr>
<td></td>
<td>11 Initial diagnosis in staff physician’s office AND part of first course treatment was done at the reporting facility</td>
</tr>
<tr>
<td></td>
<td>12 Initial diagnosis in staff physician’s office AND all first course treatment or a decision not to treat was done at the reporting facility</td>
</tr>
<tr>
<td></td>
<td>13 Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.</td>
</tr>
</tbody>
</table>
# Class of Case

## Analytic Classes of Case

### Initial diagnosis at reporting facility

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility</td>
</tr>
</tbody>
</table>

### Initial diagnosis elsewhere

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS</td>
</tr>
<tr>
<td>21</td>
<td>Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility</td>
</tr>
<tr>
<td>22</td>
<td>Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility</td>
</tr>
</tbody>
</table>
### Non-Analytic Classes of Case

**Patient appears in person at reporting facility**

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only) NOTE: The 2010 FORDS Manual changed the definition Class of Case = 30 the CoC added a new component to what previously had been “consult only.” The addition is for cases where the facility is part of the “staging workup after initial diagnosis elsewhere.” These cases are “analytic” to FCDS and in Florida a “consult only” case only refers to a case where the facility provides a second opinion without additional testing.</td>
</tr>
<tr>
<td>31</td>
<td>Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care</td>
</tr>
<tr>
<td>32</td>
<td>Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence (active disease)</td>
</tr>
</tbody>
</table>
### Class of Case

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (&lt;em&gt;disease not active&lt;/em&gt;)</td>
</tr>
<tr>
<td>34</td>
<td>Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility</td>
</tr>
<tr>
<td>35</td>
<td>Case diagnosed before program’s Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility</td>
</tr>
<tr>
<td>36</td>
<td>Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility</td>
</tr>
<tr>
<td>37</td>
<td>Case diagnosed before program’s Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility</td>
</tr>
<tr>
<td>38</td>
<td>Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death</td>
</tr>
<tr>
<td>40</td>
<td>Diagnosis AND all first course treatment given at the same staff physician’s office</td>
</tr>
<tr>
<td>41</td>
<td>Diagnosis and all first course treatment given in two or more different staff physician offices</td>
</tr>
</tbody>
</table>
# Class of Case

## Non-Analytic Classes of Case

<table>
<thead>
<tr>
<th>Patient appears in person at reporting facility</th>
</tr>
</thead>
<tbody>
<tr>
<td>42 Non-staff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility)</td>
</tr>
<tr>
<td>43 Pathology or other lab specimens only</td>
</tr>
<tr>
<td>49 Death certificate only</td>
</tr>
<tr>
<td>99 Non-analytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases)</td>
</tr>
</tbody>
</table>
Social Security Number

- SSN is a required data item
- FCDS relies heavily on correct SSN in abstracts
- Healthcare payments rely heavily on correct SSN on bill
- AHCA only includes DOB and SNN – no names

- Partial SSN
- SSN not available
- SSN not accessible to me
- How to locate SSN in medical record
- Future of SSN in cancer registration and FCDS
- What to do when AHCA SSN and Registry SSN don’t match?
Inflammatory Carcinoma of Breast

- Inflammatory carcinoma of the breast is a clinico-pathologic entity characterized by diffuse erythema and edema (peau d'orange) of the breast, often without underlying mass.
- Inflammatory carcinoma is primarily a clinical diagnosis with skin changes that usually arise quickly in the affected breast.
- A biopsy is required to demonstrate cancer either within the dermal lymphatics or in the breast parenchyma itself.
- Involvement of dermal lymphatics alone does not indicate inflammatory carcinoma in the absence of clinical findings.
- Clinical findings should involve majority of the skin of breast.
- The term of inflammatory carcinoma should not be applied to a patient with neglected locally advanced cancer of the breast presenting late in the course of her disease.
Plasma Cell Neoplasm Staging
# Plasma Cell Neoplasm Staging

## Table 1: The Durie-Salmon Staging System for Multiple Myeloma

<table>
<thead>
<tr>
<th>Stage</th>
<th>Hemoglobin</th>
<th>Calcium</th>
<th>Myeloma Protein</th>
<th>Bone Lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia</td>
<td>&gt;10 g/dL</td>
<td>Normal or ≤12 g/dL</td>
<td>IgG peak &lt;5 g/dL, IgA peak &lt;3 g/dL, Bence-Jones protein &lt;4 g/24 h</td>
<td>None or solitary bone plasmacytoma only</td>
</tr>
<tr>
<td>IIb</td>
<td>Not I or III</td>
<td>Not I or III</td>
<td>Not I or III</td>
<td>Not I or III</td>
</tr>
<tr>
<td>IIIc</td>
<td>&lt;8.5 g/dL</td>
<td>&gt;12 mg/dL</td>
<td>IgG peak &gt;7 g/dL, IgA peak &gt;5 g/dL, Bence-Jones protein &gt;12 g/24 h</td>
<td>&gt;3 lytic lesions</td>
</tr>
</tbody>
</table>

*a Stage I must demonstrate all of the criteria.

*b Stage II defined as all patients who do not qualify as Stage I or III.

*c Stage III must demonstrate one or more of the criteria.

Source: Reference 7.
Plasma Cell Neoplasm Staging

MyelomaPlasmaCellDisorder

Plasma Cell Disorders including Myeloma

- 9731 Plasmacytoma, NOS (except C441, C690, C695-C696)
- 9732 Multiple myeloma (except C441, C690, C695-C696)
- 9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696)
- Note 1: This schema was added in V2003. Originally these histologies were part of the HemeRetic schema.
- Note 2: AJCC does not define TNM staging for this site.

Collaborative Stage for TNM 7 - Revised 10/25/2011

<table>
<thead>
<tr>
<th>CS Tumor Size</th>
<th>= 988</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS Extension</td>
<td>= 9</td>
</tr>
<tr>
<td>CS Tumor Size/Ext Eval</td>
<td>= 9</td>
</tr>
<tr>
<td>CS Lymph Nodes</td>
<td>= 9</td>
</tr>
<tr>
<td>CS Lymph Nodes Eval</td>
<td>= 99</td>
</tr>
<tr>
<td>Regional Nodes Positive</td>
<td>= 99</td>
</tr>
<tr>
<td>Regional Nodes Examined</td>
<td>= 99</td>
</tr>
<tr>
<td>CS Mets at DX</td>
<td>= 9</td>
</tr>
<tr>
<td>CS Mets Eval</td>
<td>= 9</td>
</tr>
<tr>
<td>CS Site-Specific Factor 1</td>
<td></td>
</tr>
<tr>
<td>OBsolete - Janus Kinase 2 (JAK2) (also known as JAK2 Exon 12)</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 2</td>
<td></td>
</tr>
<tr>
<td>Durie-Salmon Staging System</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 3</td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma Terminology</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 4</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 5</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 6</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 7</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 8</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 9</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 10</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 11</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 12</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 13</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 14</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 15</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 16</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 17</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 18</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 19</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 20</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 21</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 22</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 23</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 24</td>
<td>= 988</td>
</tr>
<tr>
<td>CS Site-Specific Factor 25</td>
<td>= 988</td>
</tr>
</tbody>
</table>
Plasma Cell Neoplasm Staging

- **CS Extension**

- **Note 1:** Osseous plasmacytomas are localized tumors occurring in the bone. There may be soft tissue extension.

- **Note 2:** Extraosseous (extramedullary) plasmacytomas are plasma cell neoplasms that arise in tissues other than bone. The most common sites are the upper respiratory tract, the gastrointestinal tract, lymph nodes, bladder, central nervous system (CNS), breast, thyroid, testis and skin.

- **Note 3:** Criteria for the diagnosis of multiple myeloma include: presence of clonal bone marrow plasma cells or plasmacytoma, presence of an M-protein in serum and/or urine, and the presence of related organ or tissue impairment. Do not use this criteria to determine the diagnosis of multiple myeloma. Code according to histologic confirmation or physician statement according to the AJCC 7th edition.

- **Note 4:** Multiple myeloma or plasma cell myeloma is a widely disseminated plasma cell neoplasm, characterized by a single clone of plasma cells derived from B cells that grows in the bone marrow. It is always coded to 810 or 820 for systemic involvement.
# Plasma Cell Neoplasm Staging

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>Localized disease (single/solitary/unifocal/isolated mono-ostotic), may be coded for: Plasmacytoma, NOS (M-9731/3) (solitary myeloma) Plasmacytoma, extramedullary (M-9734/3) (not occurring in bone)</td>
</tr>
<tr>
<td>110</td>
<td>Single plasmacytoma lesion WITHOUT soft tissue extension or unknown if soft tissue extension (9731)</td>
</tr>
<tr>
<td>200</td>
<td>Single plasmacytoma lesion WITH soft tissue extension (9731)</td>
</tr>
<tr>
<td>300</td>
<td>Single plasmacytoma lesion occurring in tissue other than bone (9734)</td>
</tr>
<tr>
<td>400</td>
<td>Multiple osseous or multiple extraosseous plasmacytoma lesions (9731, 9734)</td>
</tr>
<tr>
<td>500</td>
<td>Plasmacytoma, NOS (9731) Not stated if single or multiple, not stated if osseous or extraosseous</td>
</tr>
<tr>
<td>800</td>
<td>OBSOLETE DATA RETAINED V0203 Systemic disease (poly-ostotic): All histologies including those in 100</td>
</tr>
<tr>
<td>810</td>
<td>Plasma cell myeloma/multiple myeloma/myelomatosis (9732)</td>
</tr>
<tr>
<td>820</td>
<td>Myeloma, NOS Excludes plasma cell myeloma or multiple myeloma (see code 810)</td>
</tr>
</tbody>
</table>

Unknown: extension not stated Primary tumor cannot be assessed Not documented in patient record
Unknown Primary/III-Defined Site

C80.9 – Unknown Primary, NOS

C76.0 – III-Defined Sites – head, face or neck, NOS

C76.1 – III-Defined Sites – thorax, NOS

C76.2 – III-Defined Sites – abdomen, NOS

C76.3 – III-Defined Sites – pelvis, NOS

C76.4 – III-Defined Sites – upper limb, NOS

C76.5 – III-Defined Sites – lower limb, NOS
Unknown Primary/Ill-Defined Site

• Rule H. Use the topography code provided when a topographic site is not stated in the diagnosis. This topography code should be disregarded if the tumor is known to arise at another site.

Head and Neck Equivalent Terms, Definitions, Charts, Tables and Illustrations
C000-C148, C300-C329
(Excludes lymphoma and leukemia – M-9590 – 9989 and Kaposi sarcoma M9140)

When the point of origin cannot be determined, use a topography code for overlapping sites:
• C02.8 Overlapping lesion of tongue
• C08.8 Overlapping lesion of major salivary glands
• C14.8 Overlapping lesion of lip, oral cavity, and pharynx.
# Unknown Primary/Ill-Defined Site

<table>
<thead>
<tr>
<th>Site Title</th>
<th>Site Code</th>
<th>Histology Title</th>
<th>Histology Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin, Arm</td>
<td>C44.6</td>
<td>Carcinoma, Melanoma, Merkel Cell, Mycosis Fungoides, Cutaneous T-Cell Lymphoma of Arm</td>
<td>8010 8720-8970 8747 9700 9709</td>
</tr>
<tr>
<td>Soft Tissue, Arm</td>
<td>C49.1</td>
<td>Sarcoma</td>
<td>8800-8921</td>
</tr>
<tr>
<td>Peripheral Nerve, Arm</td>
<td>C47.1</td>
<td>Sarcoma</td>
<td>8800-8921</td>
</tr>
<tr>
<td>Bone, Arm</td>
<td>C40.3</td>
<td>Sarcoma (osteoc)</td>
<td>9180-9194</td>
</tr>
<tr>
<td>Lymph Nodes, Arm</td>
<td>C77.3</td>
<td>Lymphoid Neoplasms</td>
<td>See Heme DB</td>
</tr>
</tbody>
</table>
First Course of Treatment

First course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence.

- **Watch and Wait** – If first course of treatment is to do nothing but watch and wait – as soon as the patient has a change in status (rising PSA, clinical evidence of disease, etc.) – the patient has disease progression and the first course of treatment (watch and wait) is OVER. Treatment given after the change in patient cancer status is subsequent TX.

- **Do not code ancillary drugs as treatment** – use SEER*Rx
Palliative Care or Palliative Treatment

The term “palliative” or “palliation” may be used in two different contexts: (a) as meaning non-curative and (b) as meaning the alleviation of symptoms. Either can be first course of treatment. Either can be subsequent treatment. Either can be end-of-life.

Some palliative treatments fall within the definition of cancer-directed treatment and some treat the patient but not the cancer.

Palliative treatment may qualify the patient as **analytic** if it is given as part of the planned first course of treatment.

Palliative treatment may qualify the patient as **non-analytic**, if it given as subsequent treatment for recurrence or progression.
Coding Surgery Fields Correctly

- Surgery of Primary Site
  - Do not code colostomy as 90
  - Do not code unknown if surgery performed as 99
  - Use best code available
- Scope of Regional Lymph Node Surgery
- Surgery of Other Regional or Distant Sites
- Reason No Surgery
- Date of Surgery – know what your vendor is sending FCDS
- Treatment Status – don’t forget watch & wait/observation
- Surg/Rad Seq
- Surg/Systemic Seq
One More Webinar

Tuesday
November 5, 2013
1 p.m. - 2 p.m ET - Noon - 1 p.m. CT

The Latest on Lung Cancer Screening

Speaker:
Robert A. Smith, PhD
American Cancer Society, Inc., Cancer Control Science Department

Dr. Robert A. Smith is a cancer epidemiologist and Senior Director, Cancer Screening, at the National Office of the American Cancer Society in Atlanta, Georgia, where he leads the development of cancer screening guidelines. His primary research interests are cancer epidemiology, evaluation of cancer prevention and early detection programs, multi-chronic disease models of preventive care, and quality assurance in the delivery of health services.

Dr. Smith serves on many international and national government and professional advisory committees and working groups, including the American College of Radiology Committee on Screening and Emerging Technologies; the American College of Radiology Commission on Breast Imaging; National Colonc...
References / Resources


References / Resources


NPCR Educational Materials for Cancer Registrars
- Volume 3: Data Editing and EDITS: Procedures for Central Registries
- Volume 4: Coding and Visual Editing: Procedures for Central Registries
- Volume 6: Audits: Casefinding and Reabstracting: Procedures for Central Registries

Unpublished materials provided by National Program of Cancer Registries
Questions